Determination of associated antimicrobial resistance in clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa in a public hospital in Goiânia, State of Goiás;Determinação da resistência antimicrobiana associada em isolados clínicos de Staphylococcus aureus e Pseudomonas aeruginosa em um hospital público de Goiânia, Estado de Goiás

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 42, Issue 4, 2009, Pages 404-410

  Kobayashi, Cláudia Castelo Branco Artiaga ^a,b   Sadoyama, Geraldo ^a   Vieira, José Daniel Gonçalves ^a  

^a Instituto de Pesquisas Tecnologicas   (Brazil)

^b Hospital de Urgência de Goiânia   (Brazil)

Author keywords

Associated antimicrobial resistance; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TETRACYCLINE; TIMENTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; HUMAN; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BRAZIL; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS, PUBLIC; HUMANS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES; RISK; STAPHYLOCOCCUS AUREUS;

PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 70349925650     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822009000400009     Document Type: Article

References (32)

1. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrobial Agents and Chemotherapy 50: 43-48, 2006.
2. Alyaseen SA, Piper KE, Rouse MS, Steckelberg JM, Patel R. Selection of crossresistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime. Antimicrobial Agents and Chemotherapy 49: 2543-2545, 2005.
3. Bernardes RC, Jorge AOC, Leão MVP. Sensibilidade à oxacilina, vancomicina e teicoplanina de Staphylococcus coagulase-positivos isolados de pacientes hospitalizados em São José dos Campos. Revista Biociências 10: 73-78, 2004.
4. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute 27: 1-182, 2007.
5. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS. Adverse Clinical and Economic Outocomes Attributable to Methicillin Resistance among Patients with Staphylococcus aureus Surgical Site Infection. Clinical Infectious Diseases 36: 592-598, 2003.
6. Figueiredo EAP, Ramos H, Maciel MAV, Vilar MCM, Loureiro NG, Pereira RG. Pseudomonas aeruginosa: freqüência de resistência a múltiplos fármacos e resistência cruzada entre antimicrobianos no Recife/PE. Revista Brasileira de Terapia Intensiva 19: 421-427, 2007.
7. Fluit AC, Wielders CLC, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3051 Staphylococcus aureus isolates from 25 University Hospitals participating in the European SENTRY study. Journal of Clinical Microbiology 39: 3727-3732, 2001.
8. Hernández NMR, López NF, Hernández MHE, Ferrer AF. Patrones de drogorresistencia de cepas de Staphylococcus aureus de origen clínico humano. Revista Cubana de Medicina Tropical 53: 53-58, 2001.
9. Kahlmeter G, Menday P. Cross resistance and associated resistance in 2478 Escherichi coli from the Pan-European ECO.SENS project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. Journal of Antimicrobial Chemotherapy 52: 128-131, 2003.
10. Kim HB, Jang HC, Nam HJ, Lee YS, Kim BS, Park WB, Lee KD, Choi Y J, Park SW, Oh MD, Kim EC, Choe KW. In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolated from tertiary-care hospitals in Korea: a nationwide survey. Antimicrobial Agents and Chemotherapy 48: 1124-1127, 2004.
11. o Simpósio Internacional de Microbiologia Clínica, Gramado, p.658, 2008a.
12. o Simpósio Internacional de Microbiologia Clínica, Gramado, p. 654, 2008b.
13. Kola A, Kirschner P, Gohrbandt B, Chaberny IF, Mattner F, Struber M, Gastmeier P, Suerbaum S. An infection with linezolid-resistant S. aureus in a patient with left ventricular assit system. Scandinavian Journal of Infectious Diseases 39: 463-465, 2007.
14. Leão LSNO, Passos XS, Reis C, Valadão LMA, Silva MRR, Pimenta FC. Fenotipagem de bactérias isoladas em hemoculturas de pacientes críticos. Revista da Sociedade Brasileira de Medicina Tropical 40: 537-540, 2007.
15. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 46: 2920-2925, 2002.
16. a edição, Ministério da Saúde. Brasília. p. 1-95, 2004.
17. Mcgowan JE. Resistance in nonfermenting gram-negative bactéria: multidrug resistance to the maximum. American Journal of Infection Control 34: S29-S37, 2006. (Pubitemid 43928175)
18. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clinical Infectious Diseases 39: 1010-1015, 2004.
19. Miller LG, Quan C, Shay A, Mostafaie K, Bharadwa K, Tan N, Matayoshi K, Cronin J, Tan J, Tagudar G, Bayer AS. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and-susceptible Staphylococcus aureus skin infection. Clinical Infectious Diseases 44: 483-492, 2007.
20. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eighth edition. NCCLS document M2-A8. National Committee for Clinical Laboratory Standards, 23: p.1-58, 2003.
21. Nouér SA, Nucci M, De-Oliveira MP, Pellegrino FLPC, Moreira BM. Risk factors for Acquisitilon of Multidrug-Resistant Pseudomonas aeruginosa Producing SPM Metallo-beta-lactamase. Antimicrobial Agents Chemotherapy 49: 3663-3667, 2005.
22. Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, Onimus T, Saulnier F, Mathieu D, Durocher A. First-generation fluoroquinolone use and subsequent emergente of multiple drug-resistance bacteria in the intensive care unit. Critical Care Medicine 33: 283-289, 2005. (Pubitemid 40216539)
23. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clinical Infectious Diseases 38: 670-677, 2004.
24. Paviani ER, Stadnik CB, Heinek I. Estudo da epidemiologia e perfil de sensibilidade da Pseudomonas aeruginosa. Infarma 15: 66-70, 2004.
25. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zocolli C, Barth A, Jones RN. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Brazilian Journal of Infectious Diseases 5: 200-214, 2001.
26. Sadoyama G, Gontijo Filho PP. Risk factors for methicillin resistant and sensitive Staphylococcus aureus infection in a Brazilian University Hospital. The Brazilian Journal of Infectious Diseases 4: 135-143, 2000.
27. Shannon KP, French GL. Increasing resistance to antimicrobial agents of gramnegative organisms isolated at a London teaching hospital, 1995-2000. Journal of Antimicrobial Chemotherapy 53: 818-825, 2004.
28. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrobial Agents and Chemotherapy 51: 423-428, 2007.
29. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo- -lactamases: the quiet before the storm? Clinical Microbiology Reviews 18: 306-325, 2005.
30. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerging Infectious Diseases 9: 1415-1422, 2003.
31. Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, Mcdougal LK, Zhu W, Musser KA, Thompson J, Kohlerschmidt D, Dumas N, Limberger RJ, Patel JB. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrobial Agents and Chemotherapy 51: 231-238, 2007.
32. Wimmerstedt A, Kahlmeter G. Associated antimicrobial resistance in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes. Clinical Microbiology and Infection 14: 315-321, 2008.